WASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- Companies that manufacture products containing nanomaterials must immediately institute high-quality risk management and product stewardship measures to limit potential liability exposure in the future, assert attorneys Jesse Ash, Antony Klapper and James Wood.
This issue will be thoroughly explored at FDLI's 2nd Annual Conference on Nanotechnology Law, Regulation and Policy, February 18-19, 2009, in Washington, D.C., and discussed in a book to be published by FDLI February 17, Nanotechnology & FDA-Regulated Products: The Essential Guide. At the conference, six top officials of the Food and Drug Administration will answer questions about how the new Administration intends to regulate nanotechnology products.
In their Insighter article on the Food and Drug Law Institute's website (www.fdli.org), Ash, Klapper and Wood, part of a team of more than two dozen attorneys involved in nanotechnology issues at the law firm of Reed Smith, note that while there has not been a single lawsuit filed where someone claimed injury because they were exposed to engineered nanomaterials, many scientists are raising questions regarding the manufacturing of nanomaterials and its effects on workforces, researchers and consumers. "For example," they write in the Insighter piece, "some scientists wonder whether engineered nanomaterials will become the next asbestos."
The attorneys point out that a recent study indicated that certain types of carbon nanotubes, graphite-based structures commonly used in nanotechnology applications, both resemble and behave like asbestos fibers. Because they are as light as plastic and stronger than steel, carbon nanotubes will likely see use in a variety of new applications, including medical nanodevices. Based on toxicity studies, scientists found that inhaling long, thin multi-walled carbon nanotubes had the potential to cause lung disorders similar to those caused by exposure to asbestos. Because there are many unanswered questions regarding risk, it is essential that companies follow the principles of good product stewardship activities and good risk management strategies in the design and manufacturing of products made with engineered nanomaterials, the authors conclude.
To register for the conference, order the book or view the entire Insighter article, visit www.fdli.org
|SOURCE Food and Drug Law Institute|
Copyright©2009 PR Newswire.
All rights reserved